title: [Multivariate analysis of clinicopathologic factors correlated with pathological complete response following preoperative radiotherapy in rectal adenocarcinoma].
abstract: OBJECTIVE
  Patients with locally advanced rectal cancer undergoing preoperative radiotherapy have disparity in pathological tumor regression. This study was to investigate clinicopathologic factors correlated with pathological complete response (pCR) following preoperative radiotherapy in rectal adenocarcinoma.
  
  
  METHODS
  In total 132 patients with rectal adenocarcinoma received preoperative radiation from January 2002 to June 2008 at Sun Yat-sen University Cancer Center. Pathological tumor response after radiation was evaluated, and correlations of pCR to 12 clinicopathologic factors were analyzed using logistic regression method.
  
  
  RESULTS
  A total of 18 patients achieved pCR after preoperative radiation, with a pCR rate of 13.6%. Univariate analysis showed that pretreatment T stage with or without concomitant chemotherapy, pretreatment serum CEA level, and CA199 level were correlated with pCR after preoperative radiation in rectal adenocarcinoma. Multivariate analysis revealed that pretreatment serum CEA level and with or without concomitant chemotherapy were independent factors for pCR after radiotherapy in rectal adenocarcinoma.
  
  
  CONCLUSIONS
  Patients undergoing preoperative radiochemotherapy with a low pretreatment serum CEA level were more likely to achieve pCR.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, PR China.
authors.forename: Jun-Zhong
authors.initials: JZ
authors.lastname: Lin
authors.forename: Zhi-Zhong
authors.initials: ZZ
authors.lastname: Pan
authors.forename: Zhi-Fan
authors.initials: ZF
authors.lastname: Zeng
authors.forename: Pei-Rong
authors.initials: PR
authors.lastname: Ding
authors.forename: De-Sen
authors.initials: DS
authors.lastname: Wan
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D011300:Preoperative Care; D012004:Rectal Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D012074:Remission Induction
chemical_list: D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil